Xeris Biopharma (XERS) Competitors

Xeris Biopharma (NASDAQ:XERS) and Zealand Pharma A/S (NASDAQ:ZEAL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, community ranking, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Does the media refer more to XERS or ZEAL?

In the previous week, Xeris Biopharma had 2 more articles in the media than Zealand Pharma A/S. MarketBeat recorded 2 mentions for Xeris Biopharma and 0 mentions for Zealand Pharma A/S. Zealand Pharma A/S's average media sentiment score of 1.08 beat Xeris Biopharma's score of 0.00 indicating that Zealand Pharma A/S is being referred to more favorably in the news media.

Company	Overall Sentiment
Xeris Biopharma	Neutral
Zealand Pharma A/S	Positive

Do analysts prefer XERS or ZEAL?

Xeris Biopharma presently has a consensus price target of $4.67, indicating a potential upside of 44.48%. Given Xeris Biopharma's higher possible upside, equities analysts plainly believe Xeris Biopharma is more favorable than Zealand Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Zealand Pharma A/S	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has higher valuation and earnings, XERS or ZEAL?

Xeris Biopharma has higher revenue and earnings than Zealand Pharma A/S. Xeris Biopharma is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$163.91M	2.94	-$62.26M	-$0.43	-7.51
Zealand Pharma A/S	$46.54M	17.59	-$161.99M	-$4.09	-4.30

Does the MarketBeat Community believe in XERS or ZEAL?

Zealand Pharma A/S received 149 more outperform votes than Xeris Biopharma when rated by MarketBeat users. However, 69.95% of users gave Xeris Biopharma an outperform vote while only 65.69% of users gave Zealand Pharma A/S an outperform vote.

Company	Underperform	Outperform
Xeris Biopharma	Outperform Votes 142 69.95%	Underperform Votes 61 30.05%
Zealand Pharma A/S	Outperform Votes 291 65.69%	Underperform Votes 152 34.31%

Which has more volatility & risk, XERS or ZEAL?

Xeris Biopharma has a beta of 2.7, suggesting that its stock price is 170% more volatile than the S&P 500. Comparatively, Zealand Pharma A/S has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.

Do institutionals & insiders hold more shares of XERS or ZEAL?

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 1.7% of Zealand Pharma A/S shares are owned by institutional investors. 4.6% of Xeris Biopharma shares are owned by company insiders. Comparatively, 2.2% of Zealand Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Is XERS or ZEAL more profitable?

Xeris Biopharma has a net margin of -32.83% compared to Zealand Pharma A/S's net margin of -565.44%. Zealand Pharma A/S's return on equity of -111.04% beat Xeris Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	-32.83%	-16,662.63%	-18.07%
Zealand Pharma A/S	-565.44%	-111.04%	-56.54%

Summary

Xeris Biopharma beats Zealand Pharma A/S on 12 of the 17 factors compared between the two stocks.